Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1Leukemia, Myeloid, Acute 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1

Interventions

Carboplatin 779Pemetrexed 606Cisplatin 543Paclitaxel 490pembrolizumab 461Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 255Nivolumab 244Bevacizumab 233osimertinib 177Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 131Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 93Ipilimumab 86Magnetic Resonance Spectroscopy 83Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × CD3 Complex × Clear all
NCT00056537 2014-08-27

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Active Biotech AB

Phase 1 Completed
44 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms

NCT00132379 2014-08-27

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

Active Biotech AB

Phase 1 Completed
13 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡